Product Description
BOS161721(avizakimab) is a fully human anti-IL-21 antibody
Mechanisms of Action: IL21 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous,Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boston Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lupus Erythematosus, Systemic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Healthy Volunteers |
2021-06-04 |
|||
| BOS161721-01 | P1 |
Completed |
Healthy Volunteers |
2018-04-27 |
62% |
2019-03-21 |
|
| BOS161721-02 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2020-11-26 |
33% |
2022-03-15 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
| 2018-000305-23 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2020-11-26 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/09/2023 |
News Article |
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer |